|
|
- 130+ participants
- In excess of 75 individual organisations represented
- 33 hours of presentations
- Over 10 hours of networking
- 91% of our attendees ranked the congress as good or excellent
- 30 different countries
› Benefits of sponsoring
|
Conference:
Pre-conference workshop
23 Feb 9am - 5pm
Day 1
24 Feb 8.30am - 6:00pm
Day 2
25 Feb 8.30am - 5:30pm
Post-conference workshop
26 Feb 9am - 5pm
Venue:
The Royal Horseguards Hotel, London, United Kingdom
› Email a friend
› Add this to my calendar
|
|
|
|
Day two - Thurs 25 Feb 2010 Day two - Thurs 25 Feb 2010
8.30am Registration and coffee 8.50am Opening remarks from the chair9am Role of generic medicines in the provision of affordable and effective healthcare
• Government initiatives to lower healthcare costs
• Generics consumption prognosis in the worldwide economical crisis with declining sales for pharmaceuticals
• Providing affordable medicines in a fiercely competitive environment with constant price erosion
Executive Vice President, Third Party Business, Actavis Group
9.30am Global growth strategies for generics• Access strategies for new markets
• Operating globally, while conducting business locally
• Key successes
Vice President & Regional Director Europe, Ranbaxy Europe Limited
10am Sub-prime generics – the new world• Re-assessing the attraction for generics – is the tide ebbing?
• The classic bundling of generic portfolios – toxic assets!
• The changing dynamics of the industry and it’s impact
• The cost of compliance and why getting it wrong can be disastrous
• ‘Thinking small’ and ‘winning big’
• Glenmark and its approach to building a sustainable generic business
Senior Vice President, European Business, Glenmark Generics
11am Licensing and acquisition strategies for increasing revenue and accelerating growth in key markets
International Market Focus11.30am Review of market dynamics in Central Eastern Europe• Review of strategies being implemented in CEE
• How are companies managing key challenges?
• Operational realities
12pm The role of regional companies in the emerging MENA markets• Consolidation of the MENA
• The future of healthcare expenditure
• How MENA markets will reform
Group Vice Chairman, Hikma Pharmaceuticals
1.30pm Market Review Southern African- Opportunities and Challenges• Background to the RSA region – demographics, healthcare financing, disease pattern etc,
• Industry health check
• Factors affecting access
• Opportunities
Joint Deputy Chief Executive, Cipla Medpro
2pm Opportunities and challenges for generic pharmaceuticals in China• Market dynamics
• Impact and changes in regulatory infrastructure
Dr Wei Huacheng, Chairman, Beijing Pharmaceutical Group Co. / Beijing Double Crane Pharmaceutical Co
2.30pm Opportunities and challenges for biosimilar development in ChinaDavid Chen, Executive VP, COO, 3SBIO, Inc
Dr Gopalan Narayanan, Manager & Head, Biologicals & Biotechnology Unit, MHRA
Wholesale and distribution environment3.30pm Wholesale and purchasing environment for generic medicines in Western Europe• What decisions big wholesalers make when selecting a generics label in their market
• How much do patients care about the brand?
• How do they see the generics medicines market evolving?
Commercial Director and Chief Executive Officer, Almus Pharmaceuticals
Research and Development with Generics4pm Role of R&D in generic medicines’ lifecycle management• Definition of “lifecycle management of a generic product”
• Planning the program
• Timing of the program
• Lifecycle management of innovator products as compared to generics
• Review examples of the lifecycle scenario of generic products. Expectations from different possible generic marketing situations, (ie. first to files, commodities, specialty products)
• Development of lifecycle management strategies to answer the needs or challenges of the “natural” lifecycle of a generic product
Vice President Product Development, Sandoz
4.30pm Panel Session:International IP developments• Recent legal developments affecting the generics industry
• Strategies to combat life cycle management
• Biosimilars – legal and commercial
Chris Thornham,
(Confirmed) Associate, Intellectual Property Group, SJ Berwin LLP
5pm Closing remarks from the chair & afternoon tea |
|
|
|
|
Robert Wessman
Executive Chairman
Alvogen
Petra Danielsohn-Weil
European President, Established Brands
Pfizer
Satish Reddy
Chief Operating Officer & Managing Director
Dr Reddy's Laboratories
Gerard van Odijk
President & Chief Executive Officer
Teva Pharmaceuticals Europe
Honorable Henry A Waxman
Member of Congress
United States of Americas
|
|
|
|
|
